Cargando…

Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations

BACKGROUND: Visceral adipose tissue (VAT) area is a strong predictor of obesity-related cardiometabolic alterations, but its measurement is costly, time consuming and, in some cases, involves radiation exposure. Glutamate, a by-product of branched-chain-amino-acid (BCAA) catabolism, has been shown t...

Descripción completa

Detalles Bibliográficos
Autores principales: Maltais-Payette, Ina, Boulet, Marie-Michèle, Prehn, Cornelia, Adamski, Jerzy, Tchernof, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219091/
https://www.ncbi.nlm.nih.gov/pubmed/30450120
http://dx.doi.org/10.1186/s12986-018-0316-5
_version_ 1783368583938572288
author Maltais-Payette, Ina
Boulet, Marie-Michèle
Prehn, Cornelia
Adamski, Jerzy
Tchernof, André
author_facet Maltais-Payette, Ina
Boulet, Marie-Michèle
Prehn, Cornelia
Adamski, Jerzy
Tchernof, André
author_sort Maltais-Payette, Ina
collection PubMed
description BACKGROUND: Visceral adipose tissue (VAT) area is a strong predictor of obesity-related cardiometabolic alterations, but its measurement is costly, time consuming and, in some cases, involves radiation exposure. Glutamate, a by-product of branched-chain-amino-acid (BCAA) catabolism, has been shown to be increased in visceral obese individuals. In this follow-up data analysis, we aimed to investigate the ability of plasma glutamate to identify individuals with visceral obesity and concomitant metabolic alterations. METHODS: Measurements of adiposity, targeted blood metabolomics and cardiometabolic risk factors were performed in 59 healthy middle-aged women. Visceral and subcutaneous adipose tissue areas were measured by computed tomography (CT) whereas body fat and lean mass were assessed by dual-energy x-ray absorptiometry (DEXA). RESULTS: The univariate Pearson correlation coefficient between glutamate and VAT area was r = 0.46 (p < 0.001) and it was r = 0.36 (p = 0.006) when adjusted for total body fat mass. Glutamate allowed to identify individuals with VAT areas ≥100 cm(2) (ROC_AUC: 0.78, 95% CI: 0.66–0.91) and VAT ≥130 cm(2) (ROC_AUC: 0.71, 95% CI: 0.56–0.87). The optimal glutamate concentration threshold determined from the ROC curve (glutamate ≥34.6 μmol/L) had a greater sensitivity than the metabolic syndrome (MetS) and the hypertriglyceridemic waist (HTW) phenotype to identify individuals with VAT ≥100 cm(2) (83% for glutamate vs 52% for the MetS and 35% for the HTW). Variance analysis showed that women with a high circulating glutamate level (≥34.6 μmol/L) had an altered metabolic profile, particularly regarding total triglyceride levels and the amount of triglycerides and cholesterol in very-low-density lipoproteins (all p < 0.01). CONCLUSION: Circulating glutamate is strongly associated with VAT area and may represent a potential screening tool for visceral obesity and alterations of the metabolic profile.
format Online
Article
Text
id pubmed-6219091
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62190912018-11-16 Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations Maltais-Payette, Ina Boulet, Marie-Michèle Prehn, Cornelia Adamski, Jerzy Tchernof, André Nutr Metab (Lond) Brief Communication BACKGROUND: Visceral adipose tissue (VAT) area is a strong predictor of obesity-related cardiometabolic alterations, but its measurement is costly, time consuming and, in some cases, involves radiation exposure. Glutamate, a by-product of branched-chain-amino-acid (BCAA) catabolism, has been shown to be increased in visceral obese individuals. In this follow-up data analysis, we aimed to investigate the ability of plasma glutamate to identify individuals with visceral obesity and concomitant metabolic alterations. METHODS: Measurements of adiposity, targeted blood metabolomics and cardiometabolic risk factors were performed in 59 healthy middle-aged women. Visceral and subcutaneous adipose tissue areas were measured by computed tomography (CT) whereas body fat and lean mass were assessed by dual-energy x-ray absorptiometry (DEXA). RESULTS: The univariate Pearson correlation coefficient between glutamate and VAT area was r = 0.46 (p < 0.001) and it was r = 0.36 (p = 0.006) when adjusted for total body fat mass. Glutamate allowed to identify individuals with VAT areas ≥100 cm(2) (ROC_AUC: 0.78, 95% CI: 0.66–0.91) and VAT ≥130 cm(2) (ROC_AUC: 0.71, 95% CI: 0.56–0.87). The optimal glutamate concentration threshold determined from the ROC curve (glutamate ≥34.6 μmol/L) had a greater sensitivity than the metabolic syndrome (MetS) and the hypertriglyceridemic waist (HTW) phenotype to identify individuals with VAT ≥100 cm(2) (83% for glutamate vs 52% for the MetS and 35% for the HTW). Variance analysis showed that women with a high circulating glutamate level (≥34.6 μmol/L) had an altered metabolic profile, particularly regarding total triglyceride levels and the amount of triglycerides and cholesterol in very-low-density lipoproteins (all p < 0.01). CONCLUSION: Circulating glutamate is strongly associated with VAT area and may represent a potential screening tool for visceral obesity and alterations of the metabolic profile. BioMed Central 2018-11-06 /pmc/articles/PMC6219091/ /pubmed/30450120 http://dx.doi.org/10.1186/s12986-018-0316-5 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Brief Communication
Maltais-Payette, Ina
Boulet, Marie-Michèle
Prehn, Cornelia
Adamski, Jerzy
Tchernof, André
Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations
title Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations
title_full Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations
title_fullStr Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations
title_full_unstemmed Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations
title_short Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations
title_sort circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219091/
https://www.ncbi.nlm.nih.gov/pubmed/30450120
http://dx.doi.org/10.1186/s12986-018-0316-5
work_keys_str_mv AT maltaispayetteina circulatingglutamateconcentrationasabiomarkerofvisceralobesityandassociatedmetabolicalterations
AT bouletmariemichele circulatingglutamateconcentrationasabiomarkerofvisceralobesityandassociatedmetabolicalterations
AT prehncornelia circulatingglutamateconcentrationasabiomarkerofvisceralobesityandassociatedmetabolicalterations
AT adamskijerzy circulatingglutamateconcentrationasabiomarkerofvisceralobesityandassociatedmetabolicalterations
AT tchernofandre circulatingglutamateconcentrationasabiomarkerofvisceralobesityandassociatedmetabolicalterations